Timeline | Published:

Prenatal and pre-implantation genetic diagnosis

Nature Reviews Genetics volume 17, pages 643656 (2016) | Download Citation

Abstract

The past decade has seen the development of technologies that have revolutionized prenatal genetic testing; that is, genetic testing from conception until birth. Genome-wide single-cell arrays and high-throughput sequencing analyses are dramatically increasing our ability to detect embryonic and fetal genetic lesions, and have substantially improved embryo selection for in vitro fertilization (IVF). Moreover, both invasive and non-invasive mutation scanning of the genome are helping to identify the genetic causes of prenatal developmental disorders. These advances are changing clinical practice and pose novel challenges for genetic counselling and prenatal care.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    1000 Genomes Project Consortium et al. A global reference for human genetic variation. Nature 526, 68–74 (2015).

  2. 2.

    , & Clinical practice. Recurrent miscarriage. N. Engl. J. Med. 363, 1740–1747 (2010).

  3. 3.

    , & Trisomy in humans: incidence, origin and etiology. Curr. Opin. Genet. Dev. 3, 398–403 (1993).

  4. 4.

    , First births to older women continue to rise. (NCHS Data Brief 152) CDC.gov (May 2014).

  5. 5.

    Statistics explained. Fertility statistics. Eurostat (updated 17 March 2016).

  6. 6.

    , , & Can comprehensive chromosome screening technology improve IVF/ICSI outcomes? A meta-analysis. PLoS ONE 10, e0140779 (2015).

  7. 7.

    & Chromosome analysis of human amniotic fluid cells. Lancet 1, 383–385 (1966).

  8. 8.

    & Intrauterine diagnosis and management of genetic defects. Am. J. Obstet. Gynecol. 99, 796–807 (1967).

  9. 9.

    , & Prenatal aneuploidy detection in interphase cells by fluorescence in situ hybridization (FISH). Prenat. Diagn. 14, 1203–1215 (1994).

  10. 10.

    Diagnosis of Down syndrome and other aneuploidies using quantitative polymerase chain reaction and small tandem repeat polymorphisms. Hum. Mol. Genet. 2, 43–50 (1993).

  11. 11.

    et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 30, e57 (2002).

  12. 12.

    et al. Emerging patterns of cryptic chromosomal imbalance in patients with idiopathic mental retardation and multiple congenital anomalies: a new series of 140 patients and review of published reports. J. Med. Genet. 43, 625–633 (2006).

  13. 13.

    et al. Prenatal detection of unbalanced chromosomal rearrangements by array CGH. J. Med. Genet. 43, 353–361 (2006).

  14. 14.

    , , & Array-based approaches in prenatal diagnosis. Methods Mol. Biol. 838, 151–171 (2012).

  15. 15.

    et al. Chromosomal microarray versus karyotyping for prenatal diagnosis. N. Engl. J. Med. 367, 2175–2184 (2012).

  16. 16.

    et al. A prospective study of the clinical utility of prenatal chromosomal microarray analysis in fetuses with ultrasound abnormalities and an exploration of a framework for reporting unclassified variants and risk factors. Genet. Med. 16, 469–476 (2014).

  17. 17.

    et al. Experience with microarray-based comparative genomic hybridization for prenatal diagnosis in over 5000 pregnancies. Prenat. Diagn. 32, 976–985 (2012).

  18. 18.

    et al. Prenatal chromosomal microarray analysis in a diagnostic laboratory; experience with >1000 cases and review of the literature. Prenat. Diagn. 32, 351–361 (2012).

  19. 19.

    et al. Clinical utility of chromosomal microarray analysis in invasive prenatal diagnosis. Hum. Genet. 131, 513–523 (2012).

  20. 20.

    , & Genetic studies in intellectual disability and related disorders. Nat. Rev. Genet. 17, 9–18 (2016).

  21. 21.

    et al. Diagnostic exome sequencing in persons with severe intellectual disability. N. Engl. J. Med. 367, 1921–1929 (2012).

  22. 22.

    et al. The usefulness of whole-exome sequencing in routine clinical practice. Genet. Med. 16, 922–931 (2014).

  23. 23.

    et al. Exome sequencing improves genetic diagnosis of structural fetal abnormalities revealed by ultrasound. Hum. Mol. Genet. 23, 3269–3277 (2014).

  24. 24.

    et al. Exome sequencing for prenatal diagnosis of fetuses with sonographic abnormalities. Prenat. Diagn. 35, 1010–1017 (2015).

  25. 25.

    et al. Clinical diagnosis by whole-genome sequencing of a prenatal sample. N. Engl. J. Med. 367, 2226–2232 (2012).

  26. 26.

    et al. Prenatal exome sequencing for fetuses with structural abnormalities: the next step. Ultrasound Obstet. Gynecol. 45, 4–9 (2015).

  27. 27.

    et al. Fetal gender and aneuploidy detection using fetal cells in maternal blood: analysis of NIFTY I data. National Institute of Child Health and Development Fetal Cell Isolation Study. Prenat. Diagn. 22, 609–615 (2002).

  28. 28.

    et al. Presence of fetal DNA in maternal plasma and serum. Lancet 350, 485–487 (1997).

  29. 29.

    et al. Rapid clearance of fetal DNA from maternal plasma. Am. J. Hum. Genet. 64, 218–224 (1999).

  30. 30.

    et al. Non-invasive prenatal diagnosis of fetal aneuploidies using massively parallel sequencing-by-ligation and evidence that cell-free fetal DNA in the maternal plasma originates from cytotrophoblastic cells. Expert. Opin. Biol. Ther. 12, S19–S26 (2012).

  31. 31.

    et al. Non-invasive prenatal measurement of the fetal genome. Nature 487, 320–324 (2012).

  32. 32.

    , , , & Fetal fraction in maternal plasma cell-free DNA at 11–13 weeks' gestation: relation to maternal and fetal characteristics. Ultrasound Obstet. Gynecol. 41, 26–32 (2013).

  33. 33.

    , , & Noninvasive fetal sex determination using cell-free fetal DNA: a systematic review and meta-analysis. JAMA 306, 627–636 (2011).

  34. 34.

    , , & Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service. Transfusion 42, 1079–1085 (2002).

  35. 35.

    et al. Non-invasive prenatal diagnosis of single-gene disorders from maternal blood. Gene 504, 144–149 (2012).

  36. 36.

    , , & Prenatal diagnosis of myotonic dystrophy using fetal DNA obtained from maternal plasma. Clin. Chem. 46, 301–302 (2000).

  37. 37.

    , , , & Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc. Natl Acad. Sci. USA 105, 16266–16271 (2008).

  38. 38.

    et al. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc. Natl Acad. Sci. USA 105, 20458–20463 (2008).

  39. 39.

    et al. Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy. Prenat. Diagn. 32, 3–9 (2012).

  40. 40.

    et al. Noninvasive prenatal diagnosis of fetal trisomy 21 by allelic ratio analysis using targeted massively parallel sequencing of maternal plasma DNA. PLoS ONE 7, e38154 (2012).

  41. 41.

    et al. Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci. Prenat. Diagn. 32, 1233–1241 (2012).

  42. 42.

    , , , & Validation of targeted sequencing of single-nucleotide polymorphisms for non-invasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, X, and Y. Prenat. Diagn. 33, 575–579 (2013).

  43. 43.

    et al. Fetal-specific DNA methylation ratio permits noninvasive prenatal diagnosis of trisomy 21. Nat. Med. 17, 510–513 (2011).

  44. 44.

    et al. Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection. Nat. Med. 13, 218–223 (2007).

  45. 45.

    et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet. Med. 13, 913–920 (2011).

  46. 46.

    et al. Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am. J. Obstet. Gynecol. 207, 137–138 (2012).

  47. 47.

    et al. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet. Gynecol. 119, 890–901 (2012).

  48. 48.

    et al. SNP-based non-invasive prenatal testing detects sex chromosome aneuploidies with high accuracy. Prenat. Diagn. 33, 643–649 (2013).

  49. 49.

    , , , & Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet. Gynecol. 45, 249–266 (2015).

  50. 50.

    et al. Maternal mosaicism is a significant contributor to discordant sex chromosomal aneuploidies associated with noninvasive prenatal testing. Clin. Chem. 60, 251–259 (2014).

  51. 51.

    , , , & Experts' opinions on the benefit of an incidental prenatal diagnosis of sex chromosomal aneuploidy: a qualitative interview survey. Prenat. Diagn. 32, 1151–1157 (2012).

  52. 52.

    et al. Noninvasive prenatal testing using a novel analysis pipeline to screen for all autosomal fetal aneuploidies improves pregnancy management. Eur. J. Hum. Genet. 23, 1286–1293 (2015).

  53. 53.

    et al. A method for noninvasive detection of fetal large deletions/duplications by low coverage massively parallel sequencing. Prenat. Diagn. 33, 584–590 (2013).

  54. 54.

    et al. Noninvasive prenatal diagnosis of a fetal microdeletion syndrome. N. Engl. J. Med. 365, 1847–1848 (2011).

  55. 55.

    , , , & Noninvasive detection of fetal subchromosome abnormalities via deep sequencing of maternal plasma. Am. J. Hum. Genet. 92, 167–176 (2013).

  56. 56.

    et al. WISECONDOR: detection of fetal aberrations from shallow sequencing maternal plasma based on a within-sample comparison scheme. Nucleic Acids Res. 42, e31 (2014).

  57. 57.

    et al. Detection of fetal subchromosomal abnormalities by sequencing circulating cell-free DNA from maternal plasma. Clin. Chem. 61, 608–616 (2015).

  58. 58.

    et al. Clinical implementation of NIPT — technical and biological challenges. Clin. Genet. 89, 523–530 (2015).

  59. 59.

    et al. Non-invasive prenatal screening of fetal Down syndrome by maternal plasma DNA sequencing in twin pregnancies. J. Matern. Fetal Neonatal Med. 26, 434–437 (2013).

  60. 60.

    et al. Secondary findings from non-invasive prenatal testing for common fetal aneuploidies by whole genome sequencing as a clinical service. Prenat. Diagn. 33, 602–608 (2013).

  61. 61.

    , & Confined placental mosaicism as a risk factor among newborns with fetal growth restriction. Prenat. Diagn. 26, 428–432 (2006).

  62. 62.

    et al. Limited clinical utility of non-invasive prenatal testing for subchromosomal abnormalities. Am. J. Hum. Genet. 98, 34–44 (2015).

  63. 63.

    et al. Expanding the scope of non-invasive prenatal testing: detection of fetal microdeletion syndromes. Am. J. Obstet. Gynecol. 212, 332.e1–332.e9 (2014).

  64. 64.

    et al. DNA sequencing versus standard prenatal aneuploidy screening. N. Engl. J. Med. 370, 799–808 (2014).

  65. 65.

    et al. Noninvasive prenatal testing of fetal aneuploidies by massively parallel sequencing in a prospective Chinese population. Prenat. Diagn. 33, 700–706 (2013).

  66. 66.

    et al. Cell-free DNA analysis for noninvasive examination of trisomy. N. Engl. J. Med. 372, 1589–1597 (2015).

  67. 67.

    et al. Noninvasive whole-genome sequencing of a human fetus. Sci. Transl. Med. 4, 137ra76 (2012).

  68. 68.

    et al. Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci. Transl. Med. 2, 61ra91 (2010).

  69. 69.

    , , , & Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 164, 57–68 (2016).

  70. 70.

    et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc. Natl Acad. Sci. USA 112, E5503–E5512 (2015).

  71. 71.

    et al. Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study. Lancet Haematol. 2, e55–e65 (2015).

  72. 72.

    et al. Presymptomatic identification of cancers in pregnant women during noninvasive prenatal testing. JAMA Oncol. 1, 814–819 (2015).

  73. 73.

    et al. Noninvasive prenatal testing and incidental detection of occult maternal malignancies. JAMA 314, 162–169 (2015).

  74. 74.

    et al. Copy-number variation and false positive prenatal aneuploidy screening results. N. Engl. J. Med. 372, 1639–1645 (2015).

  75. 75.

    et al. Maternal incidental findings during non-invasive prenatal testing for fetal aneuploidies. Genet. Med. (2016).

  76. 76.

    & Prenatal diagnosis innovation: genome sequencing of maternal plasma. Annu. Rev. Med. 67, 419–432 (2016).

  77. 77.

    et al. Noninvasive prenatal methylomic analysis by genomewide bisulfite sequencing of maternal plasma DNA. Clin. Chem. 59, 1583–1594 (2013).

  78. 78.

    et al. Maternal plasma RNA sequencing for genome-wide transcriptomic profiling and identification of pregnancy-associated transcripts. Clin. Chem. 60, 954–962 (2014).

  79. 79.

    & Control of the sex ratio at full term in the rabbit by transferring sexed blastocysts. Nature 218, 346–349 (1968).

  80. 80.

    et al. Biopsy of human preimplantation embryos and sexing by DNA amplification. Lancet 1, 347–349 (1989).

  81. 81.

    et al. Analysis of the first polar body: preconception genetic diagnosis. Hum. Reprod. 5, 826–829 (1990).

  82. 82.

    , , & Preimplantation genetic diagnosis. Nat. Rev. Genet. 3, 941–953 (2002).

  83. 83.

    Preimplantation genetic diagnosis at 20 years. Prenat. Diagn. 30, 682–695 (2010).

  84. 84.

    et al. ESHRE PGD Consortium data collection IX: cycles from January to December 2006 with pregnancy follow-up to October 2007. Hum. Reprod. 24, 1786–1810 (2009).

  85. 85.

    , , & Pregnancies from biopsied human preimplantation embryos sexed by Y-specific DNA amplification. Nature 344, 768–770 (1990).

  86. 86.

    , , , & Birth of a normal girl after in vitro fertilization and preimplantation diagnostic testing for cystic fibrosis. N. Engl. J. Med. 327, 905–909 (1992).

  87. 87.

    , , , & Dual fluorescent in situ hybridisation for simultaneous detection of X and Y chromosome-specific probes for the sexing of human preimplantation embryonic nuclei. Hum. Genet. 89, 18–22 (1992).

  88. 88.

    , , & Fluorescent PCR: a new technique for PGD of sex and single-gene defects. J. Assist Reprod. Genet. 13, 96–103 (1996).

  89. 89.

    , , , & Preimplantation diagnosis for Fanconi anemia combined with HLA matching. JAMA 285, 3130–3133 (2001).

  90. 90.

    et al. ESHRE PGD Consortium data collection XIII: cycles from January to December 2010 with pregnancy follow-up to October 2011. Hum. Reprod. 30, 1763–1789 (2015).

  91. 91.

    The European IVF Monitoring Consortium et al. Assisted reproductive technology in Europe, 2011: results generated from European registers by ESHRE. Hum. Reprod. 31, 233–248 (2016).

  92. 92.

    , & Chromosome studies in human in vitro fertilization. Hum. Genet. 72, 333–339 (1986).

  93. 93.

    et al. What next for preimplantation genetic screening? Hum. Reprod. 23, 478–480 (2008).

  94. 94.

    Preimplantation genetic diagnosis for aneuploidy screening in early human embryos: a review. Prenat. Diagn. 22, 512–518 (2002).

  95. 95.

    et al. What next for preimplantation genetic screening? High mitotic chromosome instability rate provides the biological basis for the low success rate. Hum. Reprod. 24, 2679–2682 (2009).

  96. 96.

    et al. Preimplantation genetic screening for aneuploidy of embryos after in vitro fertilization in women aged at least 35 years: a prospective randomized trial. Fertil. Steril. 93, 364–373 (2010).

  97. 97.

    et al. Preimplantation genetic diagnosis increases the implantation rate in human in vitro fertilization by avoiding the transfer of chromosomally abnormal embryos. Fertil. Steril. 68, 1128–1131 (1997).

  98. 98.

    et al. Development and validation of an accurate quantitative real-time polymerase chain reaction-based assay for human blastocyst comprehensive chromosomal aneuploidy screening. Fertil. Steril. 97, 819–824 (2012).

  99. 99.

    et al. Preclinical validation of a microarray method for full molecular karyotyping of blastomeres in a 24- h protocol. Hum. Reprod. 25, 1066–1075 (2010).

  100. 100.

    et al. SNP microarray-based 24 chromosome aneuploidy screening is significantly more consistent than FISH. Mol. Hum. Reprod. 16, 583–589 (2010).

  101. 101.

    et al. SNP array-based copy number and genotype analyses for preimplantation genetic diagnosis of human unbalanced translocations. Eur. J. Hum. Genet. 20, 938–944 (2012).

  102. 102.

    , , & Embryos of Robertsonian translocation carriers exhibit a mitotic interchromosomal effect that enhances genetic instability during early development. PLoS Genet. 8, e1003025 (2012).

  103. 103.

    et al. In vitro fertilization with preimplantation genetic screening. N. Engl. J. Med. 357, 9–17 (2007).

  104. 104.

    et al. Preimplantation genetic screening in women of advanced maternal age caused a decrease in clinical pregnancy rate: a randomized controlled trial. Hum. Reprod. 23, 2806–2812 (2008).

  105. 105.

    et al. Chromosome instability is common in human cleavage-stage embryos. Nat. Med. 15, 577–583 (2009).

  106. 106.

    et al. Chromosomal mosaicism in human preimplantation embryos: a systematic review. Hum. Reprod. Update 17, 620–627 (2011).

  107. 107.

    , & Healthy babies after intrauterine transfer of mosaic aneuploid blastocysts. N. Engl. J. Med. 373, 2089–2090 (2015).

  108. 108.

    et al. Single-cell chromosomal imbalances detection by array CGH. Nucleic Acids Res. 34, e68 (2006).

  109. 109.

    et al. Identification of small gains and losses in single cells after whole genome amplification on tiling oligo arrays. Nucleic Acids Res. 37, e105 (2009).

  110. 110.

    , , Copy number variation by array analysis of single cells following wole genome amplification. Methods Mol. Biol. 1347, 197–219 (2015).

  111. 111.

    , , & First births after preimplantation genetic diagnosis of structural chromosome abnormalities using comparative genomic hybridization and microarray analysis. Hum. Reprod. 26, 1560–1574 (2011).

  112. 112.

    et al. PGD for reciprocal and Robertsonian translocations using array comparative genomic hybridization. Hum. Reprod. 26, 1925–1935 (2011).

  113. 113.

    et al. PGD for a complex chromosomal rearrangement by array comparative genomic hybridization. Hum. Reprod. 26, 941–949 (2011).

  114. 114.

    , , , & Single-cell whole-genome amplification technique impacts the accuracy of SNP microarray-based genotyping and copy number analyses. Mol. Hum. Reprod. 17, 335–343 (2011).

  115. 115.

    et al. Single-gene testing combined with single nucleotide polymorphism microarray preimplantation genetic diagnosis for aneuploidy: a novel approach in optimizing pregnancy outcome. Fertil. Steril. 95, 1786.e5–1786.e8 (2011).

  116. 116.

    et al. Genome-wide karyomapping accurately identifies the inheritance of single-gene defects in human preimplantation embryos in vitro. Genet. Med. 16, 838–845 (2014).

  117. 117.

    et al. Concurrent whole-genome haplotyping and copy-number profiling of single cells. Am. J. Hum. Genet. 96, 894–912 (2015).

  118. 118.

    et al. Accurate whole-genome sequencing and haplotyping from 10 to 20 human cells. Nature 487, 190–195 (2012).

  119. 119.

    et al. Detection and phasing of single base de novo mutations in biopsies from human in vitro fertilized embryos by advanced whole-genome sequencing. Genome Res. 25, 426–434 (2015).

  120. 120.

    , , & Whole-genome molecular haplotyping of single cells. Nat. Biotechnol. 29, 51–57 (2011).

  121. 121.

    et al. Genome analyses of single human oocytes. Cell 155, 1492–1506 (2013).

  122. 122.

    , , & Genome-wide detection of single-nucleotide and copy-number variations of a single human cell. Science 338, 1622–1626 (2012).

  123. 123.

    et al. Single-cell paired-end genome sequencing reveals structural variation per cell cycle. Nucleic Acids Res. 41, 6119–6138 (2013).

  124. 124.

    et al. Single-cell, genome-wide sequencing identifies clonal somatic copy-number variation in the human brain. Cell Rep. 8, 1280–1289 (2014).

  125. 125.

    et al. A new workflow for whole-genome sequencing of single human cells. Hum. Mutat. 35, 1260–1270 (2014).

  126. 126.

    et al. Clinical utilisation of a rapid low-pass whole genome sequencing technique for the diagnosis of aneuploidy in human embryos prior to implantation. J. Med. Genet. 51, 553–562 (2014).

  127. 127.

    et al. Optimizing sparse sequencing of single cells for highly multiplex copy number profiling. Genome Res. 25, 714–724 (2015).

  128. 128.

    , & Mosaicism: “survival of the fittest” versus “no embryo left behind”. Fertil. Steril. 105, 1146–1149 (2016).

  129. 129.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  130. 130.

    et al. Altered levels of mitochondrial DNA are associated with female age, aneuploidy, and provide an independent measure of embryonic implantation potential. PLoS Genet. 11, e1005241 (2015).

  131. 131.

    et al. Non-invasive imaging of human embryos before embryonic genome activation predicts development to the blastocyst stage. Nat. Biotechnol. 28, 1115–1121 (2010).

  132. 132.

    , , , & Prediction model for aneuploidy in early human embryo development revealed by single-cell analysis. Nat. Commun. 6, 7601 (2015).

  133. 133.

    et al. Dynamic blastomere behaviour reflects human embryo ploidy by the four-cell stage. Nat. Commun. 3, 1251 (2012).

  134. 134.

    et al. G&T-seq: parallel sequencing of single-cell genomes and transcriptomes. Nat. Methods 12, 519–522 (2015).

  135. 135.

    et al. Parallel single-cell sequencing links transcriptional and epigenetic heterogeneity. Nat. Methods 13, 229–232 (2016).

  136. 136.

    & Should selecting saviour siblings be banned? J. Med. Eth. 30, 533–537 (2004).

  137. 137.

    , & A leap of faith? An interview study with professionals on the use of mitochondrial replacement to avoid transfer of mitochondrial diseases. Hum. Reprod. 30, 1256–1262 (2015).

  138. 138.

    et al. Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. Eur. J. Hum. Genet. 23, 1592 (2015).

  139. 139.

    , , , & Noninvasive prenatal genetic testing: current and emerging ethical, legal, and social issues. Annu. Rev. Genom. Hum. Genet. 16, 369–398 (2015).

  140. 140.

    Ethical issues raised by common copy number variants and single nucleotide polymorphisms of certain and uncertain significance in general medical practice. Genome Med. 2, 42 (2010).

  141. 141.

    , , , & Genome-wide arrays: Quality criteria and platforms to be used in routine diagnostics. Hum. Mutat. 33, 906–915 (2012).

  142. 142.

    , , , & Estimates of penetrance for recurrent pathogenic copy-number variations. Genet. Med. 15, 478–481 (2013).

  143. 143.

    et al. Implementation of genomic arrays in prenatal diagnosis: the Belgian approach to meet the challenges. Eur. J. Med. Genet. 57, 151–156 (2014).

  144. 144.

    & Generic consent for genetic screening. N. Engl. J. Med. 330, 1611–1613 (1994).

  145. 145.

    , , & Development and validation of a measure of informed choice for women undergoing non-invasive prenatal testing for aneuploidy. Eur. J. Hum. Genet. 24, 809–816 (2015).

  146. 146.

    A new ethical landscape of prenatal testing: individualizing choice to serve autonomy and promote public health: a radical proposal. Bioethics 29, 36–45 (2015).

  147. 147.

    From prenatal genomic diagnosis to fetal personalized medicine: progress and challenges. Nat. Med. 18, 1041–1051 (2012).

  148. 148.

    et al. Single nucleotide polymorphism microarray-based concurrent screening of 24-chromosome aneuploidy and unbalanced translocations in preimplantation human embryos. Fertil. Steril. 95, 1606–1612 (2011).

  149. 149.

    et al. A quantitative comparison of single-cell whole genome amplification methods. PLoS ONE 9, e105585 (2014).

  150. 150.

    et al. Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell 148, 873–885 (2012).

  151. 151.

    & Mechanism of chimera formation during the Multiple Displacement Amplification reaction. BMC Biotechnol. 7, 19 (2007).

  152. 152.

    et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 512, 155–160 (2014).

  153. 153.

    et al. Dissecting biological “dark matter” with single-cell genetic analysis of rare and uncultivated TM7 microbes from the human mouth. Proc. Natl Acad. Sci. USA 104, 11889–11894 (2007).

  154. 154.

    , & The human cleavage stage embryo is a cradle of chromosomal rearrangements. Cytogenet. Genome Res. 133, 160–168 (2011).

  155. 155.

    et al. Genome-wide maps of recombination and chromosome segregation in human oocytes and embryos show selection for maternal recombination rates. Nat. Genet. 47, 727–735 (2015).

  156. 156.

    Zygotes segregate entire parental genomes in distinct blastomere lineages causing cleavage-stage chimerism and mixoploidy. Genome Res. 26, 1–26 (2016).

  157. 157.

    et al. Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N. Engl. J. Med. 339, 1734–1738 (1998).

  158. 158.

    et al. Prenatal exclusion of β thalassaemia major by examination of maternal plasma. Lancet 360, 998–1000 (2002).

  159. 159.

    & Noninvasive fetal genomic, methylomic, and transcriptomic analyses using maternal plasma and clinical implications. Trends Mol. Med. 21, 98–108 (2015).

  160. 160.

    & The new cytogenetics: blurring the boundaries with molecular biology. Nat. Rev. Genet. 6, 782–792 (2005).

  161. 161.

    , & Structural variation in the human genome. Nat. Rev. Genet. 7, 85–97 (2006).

Download references

Author information

Affiliations

  1. Joris Robert Vermeesch, Thierry Voet and Koenraad Devriendt are at the Centre for Human Genetics, Department of Human Genetics, University of Leuven, 49 Herestraat, Leuven 3000, Belgium.

    • Joris Robert Vermeesch
    • , Thierry Voet
    •  & Koenraad Devriendt

Authors

  1. Search for Joris Robert Vermeesch in:

  2. Search for Thierry Voet in:

  3. Search for Koenraad Devriendt in:

Competing interests

J.R.V. and T.V. are co-inventors on patent application ZL913096-PCT/EP2014/068315-WO/2015/028576 'Haplotyping and copy-number typing using polymorphic variant allelic frequencies', which is licensed to Cartagenia (Agilent Technologies).

Corresponding author

Correspondence to Joris Robert Vermeesch.

Glossary

Allele drop out

(ADO). The failure to detect an allele in a sample or the failure to amplify an allele.

Amniocytes

Cells of the fetus that are suspended in the amniotic fluid.

Aneuploidies

The presence of abnormal numbers of chromosomes in a cell. In human cells, this is typically when a cell contains either 45 or 47 chromosomes, instead of the expected 46.

Assisted reproductive techniques

Clinical approaches that are used to help infertile couples achieve a normal pregnancy. These include ovarian stimulation protocols using exogenous hormones, in vitro fertilization, intracytoplasmic sperm injection and pre-implantation genetic diagnosis.

B allele frequency

(BAF). A metric that is used to analyse the data derived from single-nucleotide polymorphism genotyping platforms and is defined as the proportion of allele B occurrence compared with the total allele A and allele B occurrences.

Blastocysts

A blastocyst is a specific stage in embryonic development. On day 5 post fertilization the structure comprises a cavity, the blastocoel, with an inner cell mass; that is, the cells that subsequently contribute to the embryo and also extra-embryonic structures surrounded by a layer of trophoblast cells that provide the fetal component of the placenta.

Blastomeres

Cells produced by cleavage of the zygote after fertilization.

Breakage–fusion–bridge cycles

Mechanisms of chromosome instability involving repeated cycles of telomeric breakage and fusion of the sister chromatids. As a consequence, the fused sister chromatids are pulled towards opposite poles during anaphase and are broken apart creating new breakpoints.

Chimeric

A condition in which an organism contains genetically distinct cell lines (that is, different parental genomes).

Chorionic villi

Villi that sprout from the chorion in the placenta to provide maximum contact area with maternal blood, allowing for efficient exchange of gasses and nutrients needed for fetal development.

Chromosomal instability

(CIN). An elevated rate of chromosome missegregation or breakage per cell division leading to aneuploidy or segmental aneuploidy.

Haplotyping

The determination of the set of alleles for consecutive loci that are present on the same chromosome.

Mixoploidy

A condition in which an organism contains cell lines with different ploidy levels (for example, diploid and triploid).

Molar pregnancies

Pregnancies in which the trophoblast proliferates like a non-cancerous tumour and grows into a swollen chorionic villi mass in the uterus known as a hydatidiform mole.

Penetrance

The conditional probability of a phenotype (specifically, the probability of being affected with disease) given an underlying genotype.

Polar body

During oogenesis the primary and secondary oocyte divide asymmetrically; that is, most of the cytoplasm is segregated into one daughter cell (which becomes the egg or ovum) and the remaining cytoplasm goes to the smaller polar bodies. In humans, the first polar body is formed following the first meiotic division of the primary oocyte (which occurs near ovulation), and a second polar body is formed following the second meiotic division of the secondary oocyte (which occurs with fertilization).

Read pairs

In paired-end sequencing, a technology in which both ends of a short linear DNA molecule are sequenced, read pairs are mapped to a reference genome with a discordant orientation or distance between them, which can pinpoint structural variants.

Trisomy rescue

A phenomenon in a trisomic zygote (which contains three copies of one chromosome) in which aneuploidy is corrected by the loss of the additional chromosome during cell division. Owing to the random loss of the extra chromosome, the resulting daughter cell might contain two copies of a chromosome from the same parent (uniparental disomy).

Trophectoderm

Cells of the outer layer of a blastocyst, which provide nutrients to the embryo and develop into the fetal part of the placenta.

Uniparental disomy

(UPD). The presence of two copies of a chromosome, or part of a chromosome, from one parent and no copy from the other parent.

Whole-exome sequencing

(WES). The isolation and subsequent sequencing of the fraction of the genome that consists of protein-coding sequences (the so-called exonic sequences). The isolation is performed by capturing the exonic segments using complementary oligonucleotides as bait.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrg.2016.97

Further reading